Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (3): 1-5.doi: 10.6040/j.issn.1671-7554.0.2017.1215
SHI Benkang
CLC Number:
| [1] Lee UJ, Scott VC, Rashid R, et al. Defining and managing overactive bladder: disagreement among the experts[J]. Urology, 2013, 81(2): 257-262. [2] Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS[J]. Am J Manag Care, 2009, 15(4 Suppl): S98-107. [3] Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States[J]. Urology, 2010, 75(3): 526-532. [4] Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study[J]. Eur Urol, 2006, 50(6): 1306-1314. [5] Wang Y, Xu K, Hu H, et al. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China[J]. Neurourol Urodyn, 2011, 30(8): 1448-1455. [6] Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction[J]. BJU Int, 2011, 108(7): 1132-1138. [7] Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States[J]. World J Urol, 2003, 20(6):327-336. [8] de Groat WC. A neurologic basis for the overactive bladder[J]. Urology, 1997, 50(6A Suppl):36-52. [9] Brading AF. A myogenic basis for the overactive bladder[J]. Urology, 1997, 50(6A Suppl):57-67. [10] Haferkamp A, Dorsam J, Elbadawi A. Ultrastructural diagnosis of neuropathic detrusor overactivity: validation of a common myogenic mechanism[J]. Adv Exp Med Biol, 2003, 539(Pt A): 281-291. [11] Gillespie JI, van Koeveringe GA, de Wachter SG, et al. On the origins of the sensory output from the bladder: the concept of afferent noise[J]. BJU Int, 2009, 103(10): 1324-1333. [12] Birder L, Andersson KE. Urothelial signaling[J]. PhysiolReviews, 2013, 93(2): 653-680. [13] Andersson KE. Bladder activation: afferent mechanisms[J]. Urology, 2002, 59(5): 43-50. [14] Lucas MG, Bosch RJ, Burkhard FC, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence[J]. Eur Urol, 2012, 62(6): 1130-1142. [15] Robinson D, Giarenis I, Cardozo L. You are what you eat: the impact of diet on overactive bladder and lower urinary tract symptoms[J]. Maturitas, 2014, 79(1): 8-13. [16] Cornu JN, Abrams P, Chapple CR, et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management-a systematic review and meta-analysis[J]. Eur Urol, 2012, 62(5): 877-890. [17] Bright E, Cotterill N, Drake M, et al. Developing and validating the International Consultation on Incontinence Questionnaire bladder diary[J]. Eur Urol, 2014, 66(2): 294-300. [18] Cartwright R, Srikrishna S, Cardozo L, et al. Validity and reliability of the patient’s perception of intensity of urgency scale in overactive bladder[J]. BJU Int, 2011, 107(10): 1612-1617. [19] Kosilov KV, Loparev SA, Ivanovskaya MA, et al. Caffeine as a probablefactor for increased risk of OAB development in elderly people[J]. Curr Urol, 2016, 9(3): 124-131. [20] Burgio KL. Influence of behavior modification on overactive bladder[J]. Urology, 2002, 60(5 Suppl 1): 72-76. [21] Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial[J]. JAMA, 2002, 288(18): 2293-2299. [22] Smith AL, Wein AJ. Recent advances in the development of antimuscarinic agents for overactive bladder[J]. Trends Pharmacol Sci, 2010, 31(10): 470-475. [23] Sicras MA, Navarro AR, Ruiz TA, et al. Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care: an observational baseline study[J]. Actas Urol Esp, 2016, 40(2): 96-101. [24] Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review[J]. J Urol, 2014, 191(4): 1003-1008. [25] Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder[J]. Eur Urol, 2013, 63(2): 296-305. [26] Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder[J]. J Urol, 2013, 189(4): 1388-1395. [27] 刘和谦. 下尿路症状药物治疗新进展[J]. 中国男科学杂志, 2015, 29(4): 66-69. LIU Heqian. Advances in drugs for lower urinary tract syndrome[J]. Chinese Journal of Andrology, 2015, 29(4): 66-69. [28] Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study(Symphony)[J]. Eur Urol, 2015, 67(3): 577-588. [29] Wallace KM, Drake MJ. Overactive bladder[J]. F1000 Res, 2015, 4. pii: F1000 Faculty Rev-1406. doi: 10.12688/f1000research.7131.1. eCollection 2015. [30] Eldred-Evans D, Sahai A. Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder[J]. Ther Adv Urol, 2017, 9(1): 3-10. [31] Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder(non-neurogenic)in adults: AUA/SUFU guideline amendment[J]. J Urol, 2015, 193(5):1572-1580. [32] Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics[J]. J Urol, 2006, 176(1): 177-185 [33] Nesbitt-Hawes EM, Won H, Jarvis SK, et al. Improvement in pelvic pain with botulinum toxin type A - Single vs. repeat injections[J]. Toxicon, 2013, 63: 83-87. doi: 10.1016/j.toxicon.2012.11.018. Epub 2012 Dec 6. [34] Doeson C, Watkins J, Khan MS, et al. Repeated botulinum toxin type a injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates[J]. Eur Urol, 2012, 61(4): 834-839. [35] Bauer RM, Gratzke C, Roosen A, et al. Patient-reported side effects of intradetrusor botulinum toxin type a for idiopathic overactive bladder syndrome[J]. Urol Int, 2011, 86(1): 68-72. [36] Shalom DF, Pillalamarri N, Xue X, et al. Sacralnerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity[J]. Am J Obstet Gynecol, 2014, 211(5): 561-565. [37] 陈国庆, 廖利民. 骶神经调节在神经源性膀胱中的应用[J]. 临床外科杂志, 2016, 24(2): 102-104. CHEN Guoqing, LIAO Limin. Application of sacral neuromodulation in the treatment of neurogenic bladder[J]. J Clin Surg, 2016, 24(2): 102-104. [38] Del Río-Gonzalez S, Aragon IM, Castillo E, et al. Percutaneous tibial nerve stimulation therapy for overactive bladder syndrome: clinical effectiveness, urodynamic, and durabilityevaluation[J]. Urology, 2017, 108: 52-58. doi: 10.1016/j.urology.2017.04.059. Epub 2017 Jul 4. [39] Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder[J]. Neurourol Urodyn, 2015, 34(3): 224-230. [40] Sutherland SE, Lavers A, Carlson A, et al. Sacral nerve stimulation for voiding dysfunction: One institution's 11-year experience[J]. Neurourol Urodyn, 2007, 26(1): 19-28. [41] Marcelissen TA, Leong RK, de Bie RA, et al. Long-term results of sacral neuromodulation with the tined lead procedure[J]. J Urol, 2010, 184(5): 1997-2000. [42] Anger JT, Cameron AP, Madison R, et al. Urologic Diseases in America P. The effect of sacral neuromodulation on anticholinergic use and expenditures in a privately insured population[J]. Neuromodulation, 2014, 17(1): 72-74. [43] Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial[J]. J Urol, 2010, 183(4): 1438-1443. [44] Peters KM, Carrico DJ, MacDiarmid SA, et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study[J]. Neurourol Urodyn, 2013, 32(1): 24-29. [45] Peters KM, Carrico DJ, Wooldridge LS, et al. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study[J]. J Urol, 2013, 189(6): 2194-2201. [46] MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder[J]. J Urol, 2010, 183(1): 234-240. |
| [1] | ZHANG De-qing, ZHU Yao-feng, MENG Hui, WANG Jun, LI Yan, SHI Ben-kang. Clinical observation on intravesical instillation of sodium hyaluronate for treatment of non-bacterial cystitis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(1): 79-82. |
| [2] | ZHEN Hongtao1, ZHANG Huaiqiang1, XU Fuyu2, et al. Correlation of TRAIL expression with prognosis of bladder transitional cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(01): 61-63. |
| [3] | . [J]. Journal of Shandong University (Health Sciences), 2022, 60(1): 118-120. |
| [4] | . [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 122-124. |
|
||
